
Kadence is developing what aims to be the first FDA approved treatment for premature ejaculation. Kadence's drug candidate is inspired by Kanna, a succulent plant native to South Africa with thousands of years of indigenous use.
Under the radar for now - more info soon.
2022
XEIA invests
2024
Kadence completes Phase 1 clinical trial
Kadence completes Phase 1 clinical trial
2026
Kadence initiates Phase 2 clinical trial
Kadence initiates Phase 2 clinical trial
Stay up to date on Human 3 - the new epoch of health, wellbeing and performance